Mendel

Clinical reasoning over unstructured records is the entire product. Hypercube abstracts, structures, and answers questions across pathology reports, genomic data, physician notes, claims, and electronic data capture records, and the company's stated design premise is that generic language models are insufficient for this task. There is no services or data brokerage layer; the platform is sold to operate on the customer's own data.

Unusually well specified because the company submitted the autonomy question itself to prospective study. The Penn evaluation is structured around three explicit arms, AI alone as an autonomous algorithm, human alone as current practice, and human plus AI where the algorithm supplies a rank ordered candidate list and abstracted elements to a research coordinator who decides. Designing a trial that isolates the autonomous configuration from the assisted one, rather than asserting that a human is in the loop, is the most rigorous treatment of this axis among trial vendors here. In deployment the tool ranks and abstracts; the coordinator determines eligibility.

The architectural claim is specific, unusual, and motivated by a stated failure mode: Hypercube pairs large language modeling with symbolic reasoning over a clinical hypergraph, adopted because the company argues pure neural approaches cannot discern clinical nuance and are susceptible to hallucination. This is the same neuro symbolic reasoning that RAAPID applies in risk adjustment. Critically, every answer is tied to discrete highlighted evidence in the original record, which the company frames as making the algorithm's failure mode immediately visible rather than obscured. Publishing the reason for an architecture choice and building for inspectable failure is a materially higher standard than describing capabilities.

Independent prospective evaluation is underway at a major academic center, which is more than most vendors in this category can show. Two University of Pennsylvania registered studies assess AI augmented record abstraction for trial prescreening, one leveraging the EA8191 INDICATE Phase III prostate cancer trial as a historical control comparison, with hypotheses covering efficiency, accuracy, and diversity of prescreening. Earlier work with Penn oncologists benchmarked the platform against GPT-4 and Llama2-7b, reporting domain specific models outperforming generic ones. The benchmark comparisons are vendor initiated, and full published results of the prospective studies were not located at the time of review, so the evidence is credible and in progress rather than settled.

Two concrete mechanisms rather than assurances. The platform is cloud agnostic and can be hosted inside the customer's own environment so patient data never leaves, and a dedicated capability de identifies PHI from clinical records. Evidence linking, where each answer traces to highlighted source text, functions as a safety control as well as a transparency one, since an unsupported assertion is visibly unsupported. What is absent is published hallucination rate measurement or formal failure mode documentation.

No explicit HIPAA or BAA commitment was located in public materials, though the customer hosted deployment option and PHI de identification capability suggest the architecture is built for regulated data. The contractual posture itself is not published.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located in the materials reviewed.

No FDA regulated pathway applies and none is claimed. The registered Penn studies explicitly record the intervention as neither an FDA regulated drug nor an FDA regulated device, consistent with a research operations tool that supports prescreening rather than making a diagnosis or directing treatment. Not rated rather than graded, since applying a clearance standard to a product outside device regulation would misrepresent both.

Notable for treating diversity as a measured study endpoint rather than a marketing claim. The Penn prospective study states a hypothesis that the human plus AI workflow improves the efficiency, accuracy, and diversity of trial prescreening, which puts equity of enrollment under formal evaluation. Given that standard prescreening is known to introduce demographic bias, testing whether AI augmentation reduces or amplifies it is the right question. Results were not available at review, and no separate governance framework or subgroup performance disclosure was located.

Integration is oriented toward the analytics stack rather than the clinical one, and is named specifically: upstream and downstream connectivity with data warehouses including Databricks and Snowflake, and business intelligence tools including Tableau and Qlik. The platform ingests structured and unstructured sources spanning notes, pathology, genomics, claims, and electronic data capture. Named connectors are a stronger disclosure than asserted interoperability, though direct EHR integration is not enumerated, which fits a product operating on warehoused clinical data rather than at the point of care.

The clearest deployment answer among the trial vendors added here, and the strongest residency position. The platform is explicitly cloud agnostic and can be hosted in the customer's own environment so that data never leaves, with vendor hosting available as an alternative rather than a requirement. For an institution unwilling to move patient records to a vendor cloud, that removes the primary objection outright. Try Me environments with synthetic data are offered for evaluation, which lets a buyer test before exposing real records.

No pricing is published. The company does make a comparative cost argument, that domain specific models can outperform generic large language models at a scalable cost, but no rates, licensing structure, or per record economics are disclosed. Evaluation access through synthetic data environments lowers the cost of assessing fit before committing, which is a partial offset.

Broader than trial matching alone. Distinct product configurations address chart review, cohort building and analysis, and trial eligibility mapping against templates that can incorporate prior authorization criteria and NCCN guidelines, serving clinical care, pharmaceutical, and diagnostics customers. Published evaluation work is concentrated in oncology, which is where unstructured record complexity is greatest, but the underlying capability is not disease specific.